Chemoenzymatic glycan editing for boosting the efficacy of cell-based cancer immunotherapy

<none>

Programme Social programme Plenary speakers Keynote speakers 1st EuroCarb Young Researcher (ECYR) Workshop CarboMet Workshop Mini symposium: Glycobiology at the LUMC and beyond Favourites/Agenda

Social programme

Plenary speakers

Keynote speakers

1st EuroCarb Young Researcher (ECYR) Workshop

CarboMet Workshop

Mini symposium: Glycobiology at the LUMC and beyond

Favourites/Agenda

Photos

Venue & Travel Venue Accommodation City of Leiden Travel directions

Venue

Accommodation

City of Leiden

Travel directions

Committees

Home

Chemoenzymatic glycan editing for boosting the efficacy of cell-based cancer immunotherapy

Peng Wu 1

1 The Scripps Research Institute, La Jolla, United States

Cancers, such as breast and colon cancer, are chronical diseases that affect millions of people worldwide. Adoptive cell transfer-based therapies have received lots of attention in recent years for treating various types of cancers. Kymriah, a chimeric antigen receptor T-cell (CAR-T) therapy that was approved recently as the first cell-based gene therapy in the United States, is a preeminent example. However, in the tumor microenvironment has evolved numerous strategies to downregulate the cytotoxicity of the transferred T cells. In this talk, I will describe a strategy that is based on chemoenzymatic editing of cell-surface glycans to boost the efficacy of cell-based immunotherapy.

Contact eurocarb@eurocarb2019.com for general questions about EUROCARB2019, or codee@eurocarb2019.com for scientific questions.

Leiden University / Leiden Institute of Chemistry lic.leidenuniv.nl

European Carbohydrate Organisation

Congress by Design www.congressbydesign.com